Page 1959 - Hematology_ Basic Principles and Practice ( PDFDrive )

1737.e2 Part VII Hematologic Malignancies

46. Daar AS, Fuggle SV, Fabre JW, et al: The detailed distribution of 70. Daser A, Mitchison H, Mitchison A, et al: Non-classical-MHC genetics
MHC Class II antigens in normal human organs. Transplantation of immunological disease in man and mouse. The key role of pro-
38(3):293–298, 1984. inflammatory cytokine genes. Cytokine 8(8):593–597, 1996.
47. Skoskiewicz MJ, Colvin RB, Schneeberger EE, et al: Widespread and 71. Fischer Lindahl K: Peptide antigen presentation by non-classical MHC
selective induction of major histocompatibility complex-determined class I molecules. Semin Immunol 5(2):117–126, 1993.
antigens in vivo by gamma interferon. J Exp Med 162(5):1645–1664, 72. Urosevic MDR HLA-G: An ace up the sleeve? 2002.
1985. 73. Gobin SJ, van den Elsen PJ: The regulation of HLA class I expression:
48. Hakem R, Le Bouteiller P, Jezo-Bremond A, et al: Differential regula- is HLA-G the odd one out? Semin Cancer Biol 9(1):55–59, 1999.
tion of HLA-A3 and HLA-B7 MHC class I genes by IFN is due to 74. Bainbridge D, Ellis S, Le Bouteiller P, et al: HLA-G remains a mystery.
two nucleotide differences in their IFN response sequences. J Immunol Trends Immunol 22(10):548–552, 2001.
147(7):2384–2390, 1991. 75. Ellis SA, Palmer MS, McMichael AJ: Human trophoblast and the
49. Hakem R, Jezo-Bremond A, Le Bouteiller P, et al: Differential transcrip- choriocarcinoma cell line BeWo express a truncated HLA Class I
tion inducibility by interferon of the HLA-A3 and HLA-B7 class-I molecule. J Immunol 144(2):731–735, 1990.
genes. Int J Cancer Suppl 6:2–9, 1991. 76. Onno M, Guillaudeux T, Amiot L, et al: The HLA-G gene is expressed
50. Marincola FM, Shamamian P, Simonis TB, et al: Locus-specific analysis at a low mRNA level in different human cells and tissues. Hum Immunol
of human leukocyte antigen class I expression in melanoma cell lines. 41(1):79–86, 1994.
J Immunother Emphasis Tumor Immunol 16(1):13–23, 1994. 77. Gobin SJ, van den Elsen PJ: Transcriptional regulation of the
51. Marincola FM, Shamamian P, Alexander RB, et al: Loss of HLA hap- MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol
lotype and B locus down-regulation in melanoma cell lines. J Immunol 61(11):1102–1107, 2000.
153(3):1225–1237, 1994. 78. Lee N, Malacko AR, Ishitani A, et al: The membrane-bound and
52. Panelli MC, Wang E, Phan G, et al: Gene-expression profiling of soluble forms of HLA-G bind identical sets of endogenous peptides
the response of peripheral blood mononuclear cells and melanoma but differ with respect to TAP association. Immunity 3(5):591–600,
metastases to systemic IL-2 administration. Genome Biol 3(7):2002. 1995.
RESEARCH0035. 79. Lopez-Botet M, Llano M, Navarro F, et al: NK cell recognition of
53. Dawkins RLD-EM, Abraham LJ: Conservation versus polymorphism of non-classical HLA class I molecules. Semin Immunol 12(2):109–119,
the MHC in relation to transplantation, immune responses and auto- 2000.
immune disease, 1991, Springer-Verlag. 80. Lee N, Goodlett DR, Ishitani A, et al: HLA-E surface expression
54. Kaufman J, Volk H, Wallny HJ: A “minimal essential Mhc” and an depends on binding of TAP-dependent peptides derived from certain
“unrecognized Mhc”: two extremes in selection for polymorphism. HLA class I signal sequences. J Immunol 160(10):4951–4960, 1998.
Immunol Rev 143:63–88, 1995. 81. Lila N, Amrein C, Guillemain R, et al: Human leukocyte antigen-G
55. Migueles SA, Sabbaghian MS, Shupert WL, et al: HLA B*5701 is expression after heart transplantation is associated with a reduced
highly associated with restriction of virus replication in a subgroup incidence of rejection. Circulation 105(16):1949–1954, 2002.
of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 82. Borrego F, Ulbrecht M, Weiss EH, et al: Recognition of human histo-
97(6):2709–2714, 2000. compatibility leukocyte antigen (HLA)-E complexed with HLA class I
56. Hildesheim A, Apple RJ, Chen CJ, et al: Association of HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection
and II alleles and extended haplotypes with nasopharyngeal carcinoma from natural killer cell-mediated lysis. J Exp Med 187(5):813–818,
in Taiwan. J Natl Cancer Inst 94(23):1780–1789, 2002. 1998.
57. Goldsmith DB, West TM, Morton R: HLA associations with naso- 83. Braud VM, Allan DS, O’Callaghan CA, et al: HLA-E binds to natural
pharyngeal carcinoma in Southern Chinese: a meta-analysis. Clin killer cell receptors CD94/NKG2A, B and C. Nature 391(6669):795–
Otolaryngol Allied Sci 27(1):61–67, 2002. 799, 1998.
58. Wank R, Thomssen C: High risk of squamous cell carcinoma of the 84. Garcia P, Llano M, de Heredia AB, et al: Human T cell receptor-
cervix for women with HLA-DQw3. Nature 352(6337):723–725, mediated recognition of HLA-E. Eur J Immunol 32(4):936–944, 2002.
1991. 85. Lee N, Llano M, Carretero M, et al: HLA-E is a major ligand for the
59. Lee JRJ, Platsoucas C, et al: Increased melanoma risk associated with natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci
the class II human leukocyte antigen DBQ1*301. Proc Ann Cancer USA 95(9):5199–5204, 1998.
Symp 1994. 86. Maier S, Grzeschik M, Weiss EH, et al: Implications of HLA-E allele
60. Marincola FM, Shamamian P, Rivoltini L, et al: HLA associations in expression and different HLA-E ligand diversity for the regulation of
the antitumor response against malignant melanoma. J Immunother NK cells. Hum Immunol 61(11):1059–1065, 2000.
Emphasis Tumor Immunol 18(4):242–252, 1995. 87. O’Callaghan CA: Molecular basis of human natural killer cell recog-
61. Braun WE: Update on kidney transplantation: increasing clinical nition of HLA-E (human leucocyte antigen-E) and its relevance to
success, expanding waiting lists. Cleve Clin J Med 69(6):501–504, 2002. clearance of pathogen-infected and tumour cells. Clin Sci 99(1):9–17,
62. Shirwan H: Chronic allograft rejection. Do the Th2 cells preferentially 2000.
induced by indirect alloantigen recognition play a dominant role? 88. Tomasec P, Braud VM, Rickards C, et al: Surface expression of HLA-E,
Transplantation 68(6):715–726, 1999. an inhibitor of natural killer cells, enhanced by human cytomegalovirus
63. Ponticelli C, Tarantino A, Vegeto A: Renal transplantation, past, present gpUL40. Science 287(5455):1031, 2000.
and future. J Nephrol 12(Suppl 2):S105–S110, 1999. 89. Carosella ED, Paul P, Moreau P, et al: HLA-G and HLA-E: fundamental
64. Adams EJ, Parham P: Species-specific evolution of MHC class I genes and Pathophysiological aspects. Immunol Today 21(11):532–534, 2000.
in the higher primates. Immunol Rev 183:41–64, 2001. 90. Wainwright SD, Biro PA, Holmes CH: HLA-F is a predominantly
65. Natarajan K, Li H, Mariuzza RA, et al: MHC class I molecules, empty, intracellular, TAP-associated MHC class Ib protein with a
structure and function. Rev Immunogenet 1(1):32–46, 1999. restricted expression pattern. J Immunol 164(1):319–328, 2000.
66. Paul P, Rouas-Freiss N, Moreau P, et al: HLA-G, -E, -F preworkshop: 91. Lepin EJ, Bastin JM, Allan DS, et al: Functional characterization of
tools and protocols for analysis of non-classical class I genes tran- HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors.
scription and protein expression. Hum Immunol 61(11):1177–1195, Eur J Immunol 30(12):3552–3561, 2000.
2000. 92. D T. The clinical relevance of non-HLA polymorphisms in transplantation.
67. P S. Polymorphism and antigenicity of HLA-MICA. 2002. 2002.
68. Cerwenka A, Lanier LL: Ligands for natural killer cell receptors: 93. Velardi A, Ruggeri L, Alessandro Moretta, et al: NK cells: a lesson
redundancy or specificity. Immunol Rev 181:158–169, 2001. from mismatched hematopoietic transplantation. Trends Immunol
69. Wilson IA, Bjorkman PJ: Unusual MHC-like molecules: CD1, Fc 23(9):438–444, 2002.
receptor, the hemochromatosis gene product, and viral homologs. Curr 94. Trowsdale J, Barten R, Haude A, et al: The genomic context of natural
Opin Immunol 10(1):67–73, 1998. killer receptor extended gene families. Immunol Rev 181:20–38, 2001.